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Background: Several treatment alternatives are available for primary breast cancer, although those for metastatic
disease or inflammation associated with tumor progression are ineffective. Therefore, there is a great need for new
therapeutic alternatives capable of generating an immune response against residual tumor cells, thus contributing
to eradication of micrometastases and cancer stem cells. The use of complex natural products is an excellent
therapeutic alternative widely used by Chinese, Hindu, Egyptian, and ancestral Latin-American Indian populations.
Methods: The present study evaluated cytotoxic, antitumor, and tumor progression activities of a gallotannin-rich
fraction derived from Caesalpinia spinosa (P2Et). The parameters evaluated in vitro were mitochondrial membrane
depolarization, phosphatidylserine externalization, caspase 3 activation, DNA fragmentation, and clonogenic activity.
The parameters evaluated in vivo were tumor growth, leukocyte number, metastatic cell number, and cytokine
production by flow cytometry.
Results: The in vitro results showed that the P2Et fraction induced apoptosis with mitochondrial membrane
potential loss, phosphatidylserine externalization, caspase 3 activation, DNA fragmentation, and decreased
clonogenic capacity of 4T1 cells. In vivo, the P2Et fraction induced primary tumor reduction in terms of diameter
and weight in BALB/c mice transplanted with 4T1 cells and decreased numbers of metastatic cells, mainly in the
spleen. Furthermore, decreases in the number of peripheral blood leukocytes (leukemoid reaction) and interleukin
6 (IL-6) serum levels were found, which are events associated with a poor prognosis. The P2Et fraction exerts its
activity on the primary tumor, reduces cell migration to distant organs, and decreases IL-6 serum levels, implying
tumor microenvironment mechanisms.
Conclusions: Overall, the P2Et fraction lessens risk factors associated with tumor progression and diminishes
primary tumor size, showing good potential for use as an adjuvant in breast cancer ER(+) treatment.
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One of the most common cancers in women worldwide is
breast cancer. Its estimated incidence is 23% (1.38 million)
new cases per year, and it comprised 14% (458,000) of all
cancer deaths in 2008 [1]. According to the Colombian
Cancer Institute, there were 551 new cases localized at the
primary site in 2009, corresponding to 10% of all newly
registered cancer cases [2]. There are several therapeutic
alternatives for breast cancer, including surgery, hormone
therapy, chemotherapy, and radiotherapy. Nonetheless,
these therapies are ineffective for metastatic disease [3].
Therefore, there is a great need for new therapeutic al-
ternatives capable of generating an immune response
against residual tumor cells, thus contributing to eradica-
tion of micrometastases and cancer stem cells [4]. The use
of complex natural products is an excellent therapeutic
alternative widely used by Chinese, Hindu, Egyptian,
and ancestral Latin-American Indian populations [5].
Biologically active compounds, such as hydrolyzable or
condensed tannins [6], have high therapeutic potential
in cancer treatment. Green tea-derived condensed tan-
nins, for example, have been extensively studied. Their
activities include tumor growth inhibition, decreased
cell proliferation, increased apoptosis, and angiogenic
suppression [7]. On the contrary, studies on the bio-
logical activity of hydrolyzable tannins are limited.
Nevertheless, reports have shown that the tannin frac-
tion derived from Eugenia jambos L. (Myrtaceae) is ac-
tive against HL60 leukemia cells, inducing apoptosis
and DNA fragmentation [8]. In addition, a gallotannin-
rich fruit extract from Terminalia chebula induces
apoptosis in the murine and human breast cancer cells
S115 and MCF-7, respectively [9].
Soluble mediators may be exchanged between tumor
cells and their microenvironment, affecting tumor growth
and promoting metastases. Such mediators may be se-
creted as a result of the interaction between the innate
and/or adaptive immune system with tumor cells, or pro-
duced by the tumor cell to modulate its surroundings for
its own benefit [10]. Several reports indicate that high IL-6
serum levels in patients with breast carcinoma indicate a
poor prognosis due to correlation with metastases in pa-
tients with untreated breast cancer [11].
Our group recently reported that a Caesalpinia spinosa-
derived fraction enriched in hydrolyzable tannins induces
a cytotoxic effect on leukemia cells (K562), apoptosis with
mitochondria membrane potential (MMP) loss, DNA
fragmentation, and a decrease in clonogenic capacity [12].
Additional reports on the same plant have shown that hy-
drolyzable tannins such as tannic acid (TA) lower the bio-
chemical marker levels associated with skin cancer and
delay the development of tumors in mouse skin [13,14].
However, reports on breast cancer have not been linked
with these plant-derived tannins.The murine breast adenocarcinoma cell line 4T1 is
poorly immunogenic and highly invasive and expresses
the estrogen receptor (ER+). When orthotopically trans-
planted into BALB/c mice, 4T1 cells are able to reproduce
stage IV human breast cancer pathology [15]. Primary
tumor metastasizes spontaneously to the lung, liver, brain,
and bone marrow [16], making this an excellent model to
study metastatic breast cancer pathophysiology and de-
velop effective therapies.
We evaluated the effects of a C. spinosa plant fraction on
4T1 cells in vitro and in vivo. The fraction induced tumor
cell apoptosis in vitro, an activity related to IL-6 secretion
by the tumor cells. In vivo, it inhibited tumor growth, re-
duced metastatic cell numbers, and reduced peripheral
blood leukocytes. Finally, IL-6 serum levels in fraction-
treated mice were lower than those in untreated mice.
Methods
Plant material, extraction and purification
Caesalpinia spinosa pods were collected in Villa de Leyva,
Boyacá, Colombia in March 2007 and identified by Luis
Carlos Jiménez from the Colombian National Herbarium
(voucher specimen number COL 523714). Authorization
to collect the vegetal material was given by “Ministerio de
Medio Ambiente y Desarrollo sostenible de Colombia”
(Nº 5 from 10 may 2011). P2Et fraction was purified and
characterized as previously described [12].
Cell culture conditions
The murine mammary tumor cell line 4T1 (a gift from
Alexzander Asea of Texas A&M Health Science Center
College of Medicine, Temple, TX, USA) was cultured in
RPMI-1640 (Eurobio, Toulouse, France) supplemented
with heat-inactivated fetal calf serum (10%) (Eurobio),
2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL
streptomycin, 0.01 M Hepes buffer, and 1 mM sodium
pyruvate (Eurobio) and incubated in a humidified environ-
ment at 37°C and 5% CO2. Tumor cells were proven Myco-
plasma-free with a MycoProbe Mycoplasma Detection Kit
(R&D Systems, Minneapolis, MN) and maintained with
ciprofloxacin (0.5 μg/mL). Cells were grown until 75% con-
fluence, removed with trypsin/EDTA 1X (Eurobio), washed
with phosphate-buffered saline (PBS) (154 mM, pH 7.2),
and suspended in supplemented RPMI-1640. Human per-
ipheral blood mononuclear cells (PBMC) and fibroblasts
obtained from normal healthy donors (with informed
consent) were used as normal cells. Normal cells were
maintained as previously reported [17]. This project was
approved by the ethics committee (founded in 2002) of the
Science Faculty at a meeting on August 21, 2007.
In vitro cytotoxicity assays
P2Et fraction and doxorubicin cytotoxic effects on nor-
mal and tumor cells were evaluated using trypan blue
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Aldrich, Saint Louis, MO) as previously reported [17].
Cell viability was assessed with a trypan blue dye exclu-
sion test. The IC50 (50% inhibition of cell growth) value
was calculated using Probit analysis (MINITAB Release
14.1; Minitab Inc. 2003 Statistical Software).
Evaluation of MMP
Cells (3 × 105) were treated with various concentrations
of P2Et fraction (34.1, 17, and 8.5 μg/mL), valinomycin
(positive control, 0.1 μg/mL) or ethanol (negative con-
trol, 0.02%) for 6, 12, 24, and 48 h. MMP was measured
using JC-1 (Sigma-Aldrich) dye as previously reported
[17]. The cells were acquired on a FACSAria I (Becton,
Dickinson and Company, Franklin Lakes, NJ) and analyzed
with FlowJo software (Tree Star Inc., Ashland, OR), which
calculated the red/green fluorescence ratios. Duplicate esti-
mations were made, and the average was expressed as
mean ± SEM in three independent experiments.
Annexin V assay
Phosphatidylserine (PS) externalization was assessed by flow
cytometry using Annexin V-Alexa Fluor 488 (Molecular
Probes, Invitrogen Corp., Carlsbad, CA) and propidium
iodide (PI) (Sigma-Aldrich) as previously reported [12].
Briefly, 4T1 cells (3 × 105) were treated with P2Et fraction
(34 and 17 μg/mL), doxorubicin (positive control, 0.51
and 0.27 μg/mL), or ethanol (negative control, 0.02%) for
24 and 48 h. After treatment, the cells were dyed with
Annexin V and PI, acquired on a FACSAria I (Becton
Dickinson), and analyzed with FlowJo software (Tree Star
Inc). Assays were performed in triplicate.
Caspase 3 activity assay
Caspase 3 activity was estimated using a caspase 3 colori-
metric assay kit (Sigma-Aldrich). Briefly, cells (2 × 105
cells) were cultured at various concentrations of P2Et frac-
tion, doxorubicin (positive control), or ethanol (negative
control, 0.02%) for 48 h. Caspase 3 activity was estimated
following the manufacturer’s instructions. The increase in
caspase 3 activity was calculated from a calibration curve
prepared with pNA standards using the following formula:
Activity, μmol pNA/min/mL = [(μmol pNA × d)/(t × v)],
where d = dilution factor, t = reaction time in min, and v =
volume of sample in milliliters.
Analysis of DNA fragmentation
Cells (3 × 105) were treated with different concentrations
of P2Et fraction (34.1 and 17 μg/mL), doxorubicin (posi-
tive control, 0.27 μg/mL) or ethanol (negative control,
0.02%) for 48 h. DAPI (4',6-diamidino-2-phenylindole;
Sigma-Aldrich)-stained cells were monitored under a
confocal microscope as previously reported [17]. Slides
were mounted using a ProLong Antifade Kit (MolecularProbes), and cells were analyzed under a fluorescence
confocal microscope (FluoView 1000; Olympus, Japan).
Clonogenic assays
The clonogenic assays were performed as previously de-
scribed [17]. Briefly, 4T1 cells (2.5 × 105 cells) were
plated (96-well plates) and treated with P2Et fraction
(34.1, 17, and 3.4 μg/mL), doxorubicin (0.51, 0.25, and
0.17 μg/mL), or ethanol (negative control, 0.02%) and in-
cubated for 6 h in a humidified environment at 37°C
and 5% CO2. After treatment, cells were re-plated onto
0.5% agar dishes (60 mm; 20,000 cells/dish), incubated
for 14 d (37°C and 5% CO2), and stained with violet
crystal (0.4% in ethanol). Cell colonies with >50 cells
were counted. Treatments were performed in triplicate,
and results are expressed as mean ± SEM.
Cytokine secretion assessment
Cytokine secretion was assessed by flow cytometry using
a BD Cytometric Bead Array (CBA) Mouse Inflamma-
tion Kit (Becton Dickinson). Briefly, 4T1 cells (2 × 106
cells) were cultured with different concentrations of
P2Et fraction (34, 17, and 3.4 μg/mL), doxorubicin (0.5,
0.27, and 0.05 μg/mL), or ethanol (negative control,
0.02%) for 6, 12, 24, and 48 h. Secreted cytokines were
acquired on a FACSAria II (Becton Dickinson) and ana-
lyzed with FCAP Array software (Becton Dickinson).
Treatments were performed in triplicate, and results are
expressed as mean ± SEM.
Mice
Female BALB/c mice, 6 to 12 weeks old and purchased
from Charles Rivers Laboratories International, Inc.
(Wilmington, MA), were housed in our animal research
facility following the established protocols of the Ethics
Committee of the Science Faculty and National and
International Legislation for Live Animal Experimenta-
tion (Colombia Republic, Law 84, 1987; Colombia
Republic, Resolution 08430, 1993; National Academy of
Sciences, 2010). Mice were housed in polyethylene cages
with food and water ad libitum, controlled temperature,
and a 12-h light/dark cycle. Before treatments, the mice
were acclimated for 1 week under standard conditions.
Acute toxicity evaluation
Female BALB/c mice (6 to 12 weeks of age) weighing ap-
proximately 25 g, were divided into groups of five and in-
oculated intraperitoneally (IP) with 1, 2, 4, and 8 mg/mL of
P2Et fraction corresponding to 40, 80, 160 and 320 mg/kg.
After 72 h, deceased animals were counted and the lethal
dose, 50% (LD50) was calculated with Probit version 14
(Minitab Inc.). To ensure no toxicity animals were treated
with two different doses of P2Et fraction (18.7 and 9.3 mg/
Kg) which corresponds to 4 times lower doses than LD50.
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4T1 cells (1 × 104) suspended in 100 μL of saline
phosphate-buffer were injected into the right mammary
fat pad (subcutaneously [SC]) on day 0. After 5 days of in-
oculation, the mice (7–8 mice/group) were treated with IP
injection of P2Et fraction (9.3 or 18.7 mg/kg) or control
vehicle twice a week. The leukocyte count was determined
weekly using a hemocytometer (ABX SAS Micros 60;
Horiba, Madrid, Spain). Blood was obtained from a small
incision made to a lateral tail vein and added directly into
an EDTA containing vial and then diluted 1:1 with PBS
and counted immediately using a Calibrated Cell Counter.
Additionally, differential counts were performed using
Wright staining. Tumors were measured with vernier cali-
pers twice a week, and tumor volume was calculated using
the following formula: tumor volume (mm3) = [(width)2 ×
length]/2 [18]. Mice were sacrificed when the primary
tumor reached 2000 mm3, and lung, spleen, liver, brain,
primary tumor, and bone samples were collected for histo-
pathology studies. Tumor weight was determined in a
high-sensitivity balance. Serum was collected by cardiac
puncture, and cytokine evaluation was performed using a
BD CBA Mouse Inflammation Kit (Becton Dickinson).
Experiments were performed twice, and the results are
expressed as the mean of two independent experiments.
To evaluate the effectiveness of oral treatment with
P2Et fraction, animals were randomly assigned in con-
trol or treatment groups (7 mice per group). One week
prior to tumor cell inoculation (day 0), the treatment
group started P2Et fraction consumption (0.306 mg/Kg
daily equivalent to dose schedule used in IP administra-
tion experiment plus an adjustment for bioavailability)
administered in water. 4T1 cells (1 × 104) suspended in
100 μL of PBS were injected into the right mammary fat
pad SC on day 7. All animals were weighed once a week
and food and water consumption was recorded once a
week. To identify and quantitate surface lung metastatic
nodules, at the end of the experiment, animals were eu-
thanized and the chest cavity and trachea was exposed
through a midline chest incision. The trachea was can-
nulated with a 30-gauge syringe, and the lungs were
slowly insufflated with India Ink (1:15 PBS). The lungsTable 1 IC50 values of P2Et fraction, gallic acid, and
doxorubicin in 4T1 and normal cells (gingival fibroblasts
and PBMC) estimated using the MTT assay
IC50 values after treatment with the
following compounds
Cell Type P2Et fraction* Gallic acid* Doxorubicin*
4T1 34.1 ± 1.6 96.2 ± 0.0 0.5 ± 0.1
PBMC + PHA > 125 ± 1.0 ND 2023 ± 0.2
Fibroblasts > 125 ± 1.0 ND 0.4 ± 0.1
*Concentration (μg/mL) ± SEM.
ND = not done.were excised en bloc and immersed in Fekete’s solution
(EtOH 70%, formaldehyde 10%, glacial acetic acid at a
60:22:1 ratio) to destain the pulmonary nodules. White
tumor nodules against a blue lung background were
counted by two independent observers.
Histopathologic analysis
After treatment with P2Et fraction, primary tumors,
lung, liver, spleen, brain, and bone tissues were dis-
sected and fixed in 10% formaldehyde (Sigma-Aldrich),
embedded in paraffin, cut into 2-μm sections, and
stained with hematoxylin and eosin (H&E). Metastatic
tumor infiltrations were evaluated for each tissue and
counted under a microscope using a micrometric grid
and counted in 5 different fields (magnification power,
10× or 40×).
Statistical analysis
Values are given as mean ± SEM. Data were analyzed by
one- and two-way ANOVA, and differences between the
control and treated groups were determined using the
Bonferroni test. Differences were considered significant
at p < 0.05 and determined with GraphPad Prism 5.0
software (La Jolla, CA, USA).
Results
P2Et fraction is cytotoxic to 4T1 tumor cells in vitro
The cytotoxicity of P2Et fraction on 4T1 cells was evalu-
ated by MTT assay. Tumor cells were treated with P2Et
fraction (at different concentrations), gallic acid, and
doxorubicin for 48 h. The fraction reduced 4T1 cell via-
bility in a dose-dependent manner with an IC50 of
34.1 μg/mL. Notably, one of the compounds present in
P2Et fraction is gallic acid, and gallic acid by itself ex-
hibits less cytotoxicity (96.2 μg/mL) than does the full
P2Et fraction. This suggests that compounds other than
gallic acid exert this cytotoxic activity [19]. Doxorubicin
was used as positive control with an IC50 of 0.5 μg/mL,
as expected (Table 1, Additional file 1: Figure S1). To
evaluate whether the fraction activity is selective enough
for tumor cells, normal fibroblasts and human mono-
nuclear cells were treated with P2Et fraction. The out-
come was that P2Et fraction exerted a slight cytotoxic
effect on normal cells at high doses where the IC50 was
more than 125 μg/mL, as shown in Table 1.P2Et fraction induces apoptosis through the
mitochondrial pathway
Defining the type of tumor cell death induced by cyto-
toxic or cytostatic agents may give information about
the patient’s response. To assess the cell death type in-
duced by P2Et fraction, we estimated loss of MMP,
externalization of PS, activation of effector caspases, and
Figure 1 MMP loss, PS externalization, and activation of caspase 3 in 4T1 cells induced by P2Et fraction. (a) 4T1 cells treated with P2Et
fraction for 6, 12, 24, or 48 h, stained with JC-1, and analyzed by flow cytometry. Ethanol (negative control) and valinomycin (positive control)
(***p < 0.001). (b) PS externalization in 4T1 cells by flow cytometry after treatment for 24 h and 48 h with P2Et fraction, doxorubicin (positive
control), or ethanol (negative control). Top panel is a representative dot plot showing the various treatments; bottom is a representative
histogram showing percent (%) PS/PI cells after 24 and 48 h of treatment. (c) Caspase 3 activity by enzyme-linked immunosorbent assay (ELISA)
after cell treatment with P2Et fraction or doxorubicin (positive control) for 48 h (***p <0.001).
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fraction at different concentrations for 6, 12, 24, and
48 h showed MMP loss in a dose-dependent manner
starting at 6 h after treatment until 48 h (Figure 1a).
Similarly, PS externalization was evidenced by Annexin
V-Alexa Fluor 488 dye, where Annexin V+/PI- cells were
early apoptotic cells (Figure 1b). In addition, the late ap-
pearance of Annexin V+/PI + cells at 48 h after treat-
ment showed the cell death was apoptotic, not necrotic.
Doxorubicin showed a typical apoptotic pattern aftertreatment for 24 and 48 h. On the other hand, caspase 3
activation was higher with P2Et fraction than with doxo-
rubicin after treatment for 48 h. Caspase 3 activation was
estimated by the cleavage of Ac-DEVD-pNA substrate
compared with ethanol treatment (Figure 1c). Finally,
DNA fragmentation was assessed and apoptotic body for-
mation was detected after DAPI staining, a distinctive cell
death characteristic after DNA fragmentation (Figure 2a).
These results confirm that P2Et fraction induces apoptosis
of tumor cells through the mitochondrial pathway.
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P2Et fraction
Clonogenic assays are regarded as the gold standard tech-
nique with which to determine antitumor activity of frac-
tions and/or isolated compounds [21]. Doxorubicin and
P2Et fraction significantly decreased 4T1 cells’ clonogenic
ability compared with the negative control (Figure 2b).
We may expect that if P2Et fraction has such an effect
in vitro, the fraction effect in vivo could be foreseen to re-
duce metastasis.
P2Et fraction induces 4T1 cells to secrete IL-6 and
monocyte chemoattractant protein-1 in vitro
It is well known that multiple cell components and the
tumor microenvironment influence breast cancer pro-
gression. Cytokines such as monocyte chemoattractant
protein-1 (MCP-1), IL-6, and matrix metalloproteinases
have been suggested to promote cancer progression [22].Figure 2 P2Et fraction decreases 4T1 cell nuclear segmentation and c
and stained with DAPI. White arrows show apoptotic cells or fragmented n
treated with P2Et fraction, ethanol (negative control), and doxorubicin (pos
three independent experiments (***p < 0.001) versus control.We evaluated the secretion of IL-6, MCP-1, IL-10, IFN-
γ, IL-12p70, and TNF-α by 4T1 cells after treatment
with P2Et fraction, doxorubicin, or ethanol (negative
control) for 6, 12, 24, and 48 h. Cell culture supernatants
were used to determined cytokine secretion by flow cy-
tometry. In basal conditions or after treatment, no sig-
nificant changes were found in IL-10, IFN-γ, IL-12p70,
or TNF-α levels (data not shown). However, IL-6 levels
were detected in cells treated with P2Et fraction com-
pared with the control (ethanol) after 6 h of treatment.
After 12 h of treatment, IL-6 levels peaked followed by a
decrease, and low levels were maintained until 48 h at
all P2Et fraction concentrations. Doxorubicin-treated
cells showed no significant increase in IL-6 levels at 6 to
24 h of treatment, but the secretion levels peaked at
48 h at a concentration corresponding with the IC50
(Figure 3a, 3b). P2Et fraction and doxorubicin can in-
duce a slight increase in MCP-1 secretion by 4T1 cellslonogenic activity. (a) 4T1 cells treated with P2Et fraction for 48 h
uclei observed under a fluorescence microscope (40×). (b) 4T1 cells
itive control). Data represent the mean number of colonies ± SEM of
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(Figure 3c, 3d). In addition to having a cytotoxic effect
on 4T1 cells, P2Et fraction and doxorubicin may also
positively modulate IL-6 and MCP-1 secretion, but with
different kinetics. Doxorubicin increased IL-6 secretion
at the IC50 concentration; while P2Et fraction increased
IL-6 secretion at all tested concentrations.
P2Et fraction inhibits 4T1 cell growth and metastasis in
BALB/c mice
To assess the chemotherapeutic effect of P2Et fraction
under physiological conditions, a murine model of meta-
static breast cancer was used after transferring 4T1 cells
into mouse mammary fat pad. The P2Et therapeutic dose
was determined following LD50 estimation as described in
the Materials and Methods. The LD50 corresponded to
69.6 mg/kg, and the therapeutic dose was 4-fold less to
ensure low toxicity (Additional file 2: Figure S2). Female
BALB/c mice in groups of 7 to 8 were inoculated with SC
injection of 1 × 104 4T1 cells. After 5 days, the tumors
were palpable, and the mice were treated with 18.7 and
9.3 mg/kg of P2Et fraction or vehicle (PBS) twice a week.
Figure 4a shows that P2Et fraction significantly reduced
tumor growth compared with the control, becoming in-
creasingly marked from day 23 until 30. Similarly, there
was a significant decrease in primary tumor weight at the
two tested concentrations (Figure 4b).Figure 3 IL-6 and MCP-1 production by 4T1 cells after treatment with
doxorubicin for 6, 12, 24, or 48 h, and IL-6 (a, b) or MCP-1 (c, d) Secretion wInoculation of 4T1 cells into mouse mammary fat pad in-
duces extramedular hematopoiesis, generating the so-
called leukemoid reaction [23], a condition also observed
in advanced human cancers. Leukocytosis of >50,000 cells/
μL is associated with an increase in tumor invasive capacity
and size, which is probably caused by tumor cell secretion
of GM-CSF [24]. Because the leukemoid reaction in several
human cancers is associated with a poor prognosis [25], we
evaluated whether P2Et fraction therapy influences the
leukocyte number in the peripheral blood of mice. The de-
crease in leukocyte number, seen since day 22, was consid-
ered significant on day 30 (Figure 4c). The latter results
suggest that P2Et fraction activity may decrease mediators
triggering the leukemoid reaction in this model, which can
be beneficial for the disease outcome.
Since the experimental model developed spontaneous
metastasis, histopathological analysis to evaluate the
number of tumor cells present in lung, liver, spleen, and
primary tumor tissues was carried out. Treated mice tis-
sues had fewer tumor cells than did untreated mice tissues
(Figure 5a, Additional file 3: Figure S3), with significant
differences in the primary tumor and spleen (Figure 5b).
Similarly, no tumor cells were found in the bone marrow
or brain tissues of either group (data not shown). P2Et
fraction exerted activity on the primary tumor as evi-
denced by the decrease in size and weight of the tumor
and the decrease in metastases in the spleen and liver.P2Et fraction in vitro. 4T1 cells were treated with P2Et fraction and
as determined by flow cytometry (***p < 0.001) versus control.
Figure 4 Tumor growth inhibition and decrease in leukemoid reaction in BALB/C mice by P2Et fraction. BALB/c mice implanted SC with
1 × 104 4T1 cells for 5 days and randomly divided into three groups. Group 1 was treated with PBS (vehicle), group 2 was treated with 18.7 mg/
kg of P2Et fraction, and group 3 was treated with 9.3 mg/kg of P2Et fraction. Leukocyte count was determined weekly using a hemocytometer
(ABX Micros 60). After 31 days, all animals were sacrificed. (a) Tumor volume. The graph represents the mean of each group with 7–8 animals per
group. (b) Tumor weight. The graph represents the total animals by each group. For these experiments we used 7–8 animals per group and each
experiment was performed independently two times. (c) Leukocyte count. The graph represents the total number animals used per group. For
these experiments we used 7–8 animals per group and each experiment was performed independently two times.
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Microenvironmental factors such as proinflammatory cy-
tokines and adhesion molecules may support tumor pro-
gression toward a malignant phenotype by favoring a
suitable environment and interactions with tumor cells
[26]. As mentioned above, cytokines such as MCP-1 and
IL-6 may promote breast cancer progression [22]. There
are also reports associating IL-6 with growth and progres-
sion of ovarian and myeloma cancers [27,28]. Thus, we
quantified IL-6, MCP-1, and the proinflammatory cyto-
kines IL-10, IFN-γ, IL-12p70, and TNF-α in treated and
control mice serum. Treated mice had significantly lower
IL-6 serum levels compared with the controls (Figure 5c).
We also observed a decreasing trend in MCP-1, although
it was not significant (Figure 5d). The other tested cyto-
kines showed no differences or were not detected in the
serum of mice (data not shown). These results suggestthat P2Et fraction diminishes the host inflammatory re-
sponse, apparently indirectly, and that this change is asso-
ciated with a decrease in tumor diameter and metastasis
control, confirming its potential antitumor function.
To determine its biological activity and bioavailability,
the P2Et fraction was orally administrated to female
BALB/c transplanted with 4T1 cells as described in detail in
the Material and Methods section. We demonstrated that
mice receiving the P2Et fraction had significantly reduced
tumor volumes as compared to control treated mice
(Figure 6a). In addition, we demonstrated that mice receiv-
ing the P2Et fraction exhibited significantly less lung macro-
metastasis as judged by India ink staining (Figure 6b).
Discussion
P2Et is a C. spinosa-derived fraction mainly composed
of hydrolyzable tannins, gallotannins, and minor
Figure 5 Reduction of spleen metastasis and decreased IL-6 serum levels in BALB/c mice treated with P2Et fraction. After treatment,
primary tumors and lung, liver, and spleen tissues were dissected and fixed in 10% formaldehyde, embedded in paraffin, and stained with H&E.
Metastatic infiltrations were evaluated in each tissue and counted using a microscope with a micrometric grid (magnification power, 10×).
(a) Tissue Images. White arrows show metastatic tumor infiltration, white dotted arrows show alveolar septum, black arrows show adipocytes,
and black dotted arrows show necrotic areas. (b) Graphic shows tissue cell number in each (***p < 0.001) versus control. The graphs represents
mean of each group with 7–8 animals by group and each experiment was performed independently two times. (c) After treatment, mice serum
was collected by cardiac puncture, and cytokine estimation was performed using a CBA mouse inflammation kit. (c) IL-6 secretion. (d) MCP-1
secretion (***p < 0.001) versus control. The graphs represents mean of each group with 7–8 animals by group and each experiment was
performed independently two times.
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ously stated [12]. Our study gives evidence of the frac-
tion’s cytotoxic effects on 4T1 cells, inducing apoptosis
by the mitochondrial pathway, a path selective for cells
with high proliferative rates when compared with nor-
mal mononuclear cells or human fibroblasts. Apoptosis
is a type of programmed cell death that can be activatedby two pathways: extrinsic and intrinsic. The latter in-
volves mitochondrial translocation of pro-apoptotic
members of the Bcl-2 family, such as Bax, causing MMP
loss followed by the release of several apoptosis media-
tors, including cytochrome c, into the cytosol [29],
which binds Apaf-1 and, in association with other pro-
teins, the apoptosome is formed. This in turn recruits
Figure 6 Tumor growth and lung metastases formation is decreased after treatment with P2Et fraction. BALB/c mice were randomly
assigned in control or treatment groups (7 mice per group). One week prior to tumor cell inoculation (day 0), the treatment group started P2Et
fraction consumption administered in water. 4T1 cells (1 × 104) were injected into the right mammary fat pad SC on day 7. After 33 days, all
animals were sacrificed. (a) Tumor volume. The graph represents the mean of each group with 7 animals per group. (b) Lung metastatic number.
White tumor nodules against a blue lung background were counted by two independent observers. The graph represents the total animals by
each group. For these experiments we used 5 animals per group.
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fector caspases such as caspase 3. Finally, DNA endonu-
cleases are activated [30,31]. This cell death pathway
involving caspase activation produces typical morpho-
logical changes such as chromatin condensation, nucleo-
somal DNA fragmentation, nuclear membrane disruption,
PS externalization, and formation of apoptotic bodies [29].
We herein demonstrated that P2Et fraction activity in-
duces apoptosis with MMP loss, PS externalization,
caspase 3 activation, and DNA fragmentation.
The activities of isolated compounds that are also
present in P2Et fraction have been previously studied.
Gallotannins or gallic acid derivatives, specifically alkyl gal-
lates and gallamides, have proven cytotoxic effects on
L1210 leukemia cells in a dose-dependent manner [32].
Eugenia jambos L. (Myrtaceae) plant extract exerts cyto-
toxic activity on HL60 leukemia cells. This extract contains
hydrolyzable tannins (1-O-galloyl castalagin, casuarinin,
and gallotannins) and induces apoptosis and DNA frag-
mentation [8]. Similarly, we previously reported that P2Et
fraction has a cytotoxic effect on leukemia cells (K562), in-
ducing apoptosis [12]. The compound’s broad activity
range can also be seen in Terminalia chebula fruit extract,
rich in gallotannins capable of inducing apoptosis in the
murine and human breast cancer cells MCF-7 and S115,
respectively, among other activities [9].
PGG is a compound also present in P2Et fraction, and
it is capable of inducing G1-phase arrest [33], suppress-
ing the phosphorylation and protein level of estrogen re-
ceptor alpha by promoting degradation in the lysosome
and negatively modulating the ErbB/PI3K/Akt pathway in
MCF-7 cells [34]. This causes the cells to become refrac-
tory to estrogenic stimulation. In our previous studies, wealso observed a G1-phase arrest in MCF-7 cells [12], but
not in 4T1 cells, suggesting a cell line-selective mechan-
ism. We also showed that the activities of gallotannins and
PGG are regulated by the same cell diversity.
Caesalpinia spinosa fruits are well known to be good
tannins sources, yet evidence of their cytotoxic or anti-
tumor activity is quite limited. Gali-Muhtasib’s group
reported that C. spinosa hydrolyzable tannins such as TA
lower skin cancer biochemical marker levels, delaying
tumor development in mice [13,14]. Similarly, epigallo-
catechin 3-gallate (EGG), a gallic acid condensed tannin
present in green tea, is capable of inducing apoptosis
through the mitochondrial pathway in murine breast can-
cer cells (4T1) [35]. In general, such compounds exhibit
low toxicity to normal cells, as observed herein and previ-
ously demonstrated for 1-O-galloyl castalagin, casuarinin,
and gallotannins from Eugenia jambos, which are slightly
cytotoxic to human lymphocytes [6].
Our study evaluated the fraction’s ability to modulate
tumor cell cytokine production. We found that both
P2Et fraction and doxorubicin induced early IL-6 secre-
tion from ER(+) 4T1 cells and in both treatments there
was apoptosis induction, inferring that IL-6 favors their
latter removal [36]. No significant changes in the levels
of the other tested cytokines were found in tumor cell
secretion. To control tumor growth in vivo, is necessary
to induce direct death of tumor cells and regulate micro-
environmental and tissue factors involved in primary
tumor proliferation and migration. IL-6 is a mediator
with dual activity in tumor growth and metastatic pro-
cesses. Intrinsic production of IL-6 in the ER(+) breast
cancer cell lines MCF-7, T47D, ZR-75-1, and SK-BR pro-
motes cell death in response to drugs, inducing
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mentation [37-39]. On the contrary, in the ER(−) breast
cancer cell lines HS578T and MDA-MB-231, IL-6 is re-
lated to a drug-resistant phenotype with increased ex-
pression of MDR-1 [40]. In our system, IL-6 production
by 4T1 cells favored apoptotic cell death.
On the other hand, when overexpressed in organs
such as the liver, brain, or lung, IL-6 can promote me-
tastasis by attracting and promoting tumor cells [41]. In
patients with breast cancer, IL-6 is associated with a
poor prognosis because the levels increase in advanced
stages and are associated with a higher number of me-
tastases [42]. We observed a decrease in circulating IL-6
that may have been correlated with the reduction in
tumor volume and metastasis; however, it also may have
been correlated with negative regulation of the inflam-
matory microenvironment, favoring the activation of
mechanisms implied in tumor elimination.
Additional results suggest that P2Et fraction could modu-
late different mediators. When 4T1 cells are orthotopically
transplanted to BALB/c mice, a leukemoid reaction is in-
duced. This reaction is characterized by leukocytosis of
>50,000 cells/μL with predominance of immature
granulocytes Gr-1dim and splenomegaly due to massive
granulocyte infiltration into the red pulp [23]. P2Et
fraction-treated animals showed a reduced number of
peripheral blood leukocytes at day 30. The leukemoid
reaction has been associated with a poor prognosis in
animal cancer models and human cancers [25]. The de-
crease in response by P2Et fraction therapy could im-
prove the course of the disease.
The in vivo P2Et fraction activity showed that the frac-
tion favors not only a decrease in tumor diameter and
weight, but also a significant decrease in spleen and liver
metastases. 4T1 tumor cells are highly aggressive and
metastatic in BALB/c mice, causing death mostly by me-
tastasis and not by the primary tumor [16,43]. Polyphenols,
particularly EGG, reportedly have a role in metastasis con-
trol in 4T1 models [35] and that their activity is linked to
a decrease in proliferating cell nuclear antigen, resulting in
a decreased cell proliferation rate.
Tumor progression into a malignant phenotype is fa-
vored by different signals generated by microenviron-
mental factors such as proinflammatory cytokines and
adhesion molecules as well as conditions that support
the tumor microenvironment by interacting with specific
tumor cell receptors [26], promoting breast cancer pro-
gression [22]. Thus, high IL-6 serum levels are associ-
ated with lower survival, and at later stages, IL-6 can
contribute to tumor growth progression [11]. We found
that IL-6 serum levels in mice treated with P2Et fraction
were significantly lower than those in untreated mice.
Similarly, MCP-1 levels were reduced, although not sig-
nificantly. The latter findings of the decrease inleukemoid reaction and direct activity over tumor cells
allow us to conclude that P2Et fraction, besides reducing
primary tumor diameter and weight, lessens the migra-
tion to distant organs by mechanisms involving the
tumor microenvironment as shown by the decreased
serum IL6. With regards to data demonstrating that
treatment of tumor-bearing mice with P2Et fraction re-
sults in significant reduction in serum IL-6, we
hypothesize that locally produced IL-6 may improve
apoptosis mechanisms and are consumed immediately
by tumor cells during its death process thus acting in an
autocrine fashion as previously discussed. We concur
that tumor reduction after P2Et treatment cannot simply
explain IL-6 serum reduction and hypothesize that some
other immune-regulatory mechanisms are mediated by the
P2Et fraction cannot be excluded, including the inhibition
of suppressor macrophages.
Overall, P2Et fraction decreases associated risk factors
and primary tumor size, supporting its potential use as
an adjuvant in ER(+) breast cancer treatment. Moreover,
it is important to note that antitumor activity of the frac-
tion is observed in immunocompetent mice; conse-
quently, tumor microenvironment modulation together
with antitumor immune response activation allows for
control of distant metastases. We are currently evaluat-
ing this hypothesis in our laboratory.Conclusions
P2Et fraction exerts its activity on the primary tumor,
reduces cell migration to distant organs, and implies
the involvement of tumor microenvironment-associated
mechanisms in the drop in IL-6 serum levels. Overall, P2Et
fraction lessens risk factors associated with tumor progres-
sion and diminishes primary tumor size, offering great po-
tential for use as an adjuvant in ER(+) breast cancer
treatment.
Additional files
Additional file 1: Figure S1. Dose–response viability curve. 4T1 cells
were seeded in 96-well plates and treated with different concentrations
of P2Et fraction (250 a 1.9 μg/mL) for 48 h. Viability were determined by
the MTT method described in Materials and Methods. The IC50 was
calculated using Probit analysis (MINITAB 14.1).
Additional file 2: Figure S2. Dose–response curve for acute lethality.
Groups of 5 BALB/c mice (6 to 12 weeks of age) were injected IP with
P2Et fraction (40, 80, 160 and 320 mg/Kg). Animals were monitored 72 h
for mortality and the lethal dose 50 (LD50) was calculated using Probit
analysis (MINITAB 14.1).
Additional file 3: Figure S3. Reduction of metastasis in BALB/c mice
treated with P2Et fraction. After treatment, primary tumors and lung, liver,
and spleen tissues were dissected and fixed in 10% formaldehyde,
embedded in paraffin, and stained with H&E. Metastatic infiltrations were
evaluated in each tissue (magnification power, 100×). White arrows show
metastatic tumor infiltration, white dotted arrows show alveolar septum,
white circles show aberrant mitotic cells and black arrows show
adipocytes.
Urueña et al. BMC Complementary and Alternative Medicine 2013, 13:74 Page 12 of 13
http://www.biomedcentral.com/1472-6882/13/74Abbreviations
CBA: Cytometric bead array; DAPI: 4,´6-diamidino-2-phenylindole;
DMSO: Dimethyl sulfoxide; EGG: Epigallocatechin 3-gallate; H&E: Hematoxylin
and eosin; IC50: 50% inhibition cell growth; IP: Intraperitoneally; IL-
6: Interleuquin 6; LD50: Lethal dosis 50; MCP1: Monocyte chemoattractan
protein-1; MMP: Mitochondria membrane potential; MTT: Methylthiazol
tetrazolium; PGG: Pentagalloylglucose; PI: Propidium iodide; PMBC: Human
peripheral blood mononuclear cells; PS: Phosphatidylserine; S.
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